Chemotherapy for Leukemia by Takanori Ueda

Author:Takanori Ueda
Language: eng
Format: epub
Publisher: Springer Singapore, Singapore

* P < 0.05

11.4.3 ATRA in Consolidation Therapy

In the LPA99 trial, the Spanish PETHEMA group reported that a risk-adapted strategy combined with ATRA and anthracycline monochemotherapy for both induction and consolidation, followed by maintenance with ATRA and low-dose methotrexate (MTX) and mercaptopurine (6MP), resulted in a higher antileukemic efficacy than in the previous LPA96 trial (Table 11.4) [74]. Intermediate- and high-risk patients received ATRA (45 mg/m2/day for 15 days) combined with anthracycline for three courses during the consolidation phase in the LPA99 study. This risk-adapted strategy combining ATRA and anthracycline monotherapy for consolidation led to significantly improved 5-year CIR and DFS rates in the intermediate-/high-risk patients (Table 11.4).Table 11.4ATRA in consolidation therapy

Download

Copyright Disclaimer:
This site does not store any files on its server. We only index and link to content provided by other sites. Please contact the content providers to delete copyright contents if any and email us, we'll remove relevant links or contents immediately.